Product Description
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Clovis Oncology
Company Location: BOULDER CO 80301
Company CEO: Patrick J. Mahaffy
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT02705339 | P2 |
Withdrawn |
Non-Small-Cell Lung Cancer |
2019-11-01 |
2019-03-20 |
Treatments |
|
| NSCLC | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2019-07-30 |
12% |
2020-08-14 |
Patient Enrollment|Primary Endpoints|Treatments |
| CO-1686-008 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2018-07-03 |
12% |
2020-01-08 |
|
| TIGER-3 | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2018-03-29 |
2019-03-20 |
Treatments |
|
| TIGER-3 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2018-03-29 |
2022-03-13 |
Treatments |
|
| CO-1686-032 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2017-09-05 |
2019-07-10 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| EGFR | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2017-06-28 |
2019-05-01 |
||
| CO-1686-033 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2016-05-05 |
2019-03-20 |
||
| CO-1686-031 | N/A |
No longer available |
Non-Small-Cell Lung Cancer |
None |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/05/2024 |
PubMed |
Identification and validation of m6A-associated ferroptosis genes in renal clear cell carcinoma. |
|
07/20/2023 |
News Article |
Agenus Expands Executive Leadership Team |
|
11/01/2022 |
PubMed |
Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer. |
|
06/01/2022 |
News Article |
Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer |
|
07/12/2021 |
News Article |
Securities & Exchange Commission ("Commission") Establishes Clovis Oncology Fair Fund - Summary Notice of Distribution |
|
02/26/2019 |
News Article |
Clovis Oncology Announces 2018 Operating Results |